Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
05/2012
05/03/2012WO2012058308A2 Antibody based reagent that specifically recognizes toxic oligomeric form of beta-amyloid
05/03/2012WO2012058220A2 Anti-sod1 antibodies and uses thereof
05/03/2012WO2012058072A1 Method of rapidly producing vaccines for animals
05/03/2012WO2012057934A1 Immunogenic agents
05/03/2012WO2012057765A1 Recombinant anti-cd19 monoclonal antibodies
05/03/2012WO2012057697A1 New diagnostic and therapeutic target
05/03/2012WO2012057671A1 New compositions and methods for treatment of autoimmune and allergic diseases
05/03/2012WO2012057613A1 Method for preventing myocardial infarction-related complications
05/03/2012WO2012057328A1 Anti-cdh3 antibody having high internalizing capability
05/03/2012WO2012057315A1 High-affinity anti-cdh3 antibody
05/03/2012WO2012057288A1 Novel anti-dr5 antibody
05/03/2012WO2012055986A1 Methods for capturing virus like particles from plants using expanded chromatography
05/03/2012WO2012055985A1 Vaccine compositions based on modified gp41 immunogens
05/03/2012WO2012055981A1 Immunogenic compositions and methods for treating neurologic disorders
05/03/2012WO2012055980A1 Antibodies for the treatment of hiv
05/03/2012WO2012055961A1 Means and methods for treating dlbcl
05/03/2012WO2012055951A2 Immunogenic composition
05/03/2012WO2012055933A1 Liposome-based construct comprising a peptide modified through hydrophobic moieties
05/03/2012WO2012055096A1 Preparation method and use of anti-fgf-23 antibody
05/03/2012WO2012055030A1 Clostridium difficile-specific antibodies and uses thereof
05/03/2012WO2012054997A1 Method for labelling with radionuclides murine or human, monoclonal or polyclonal anti-tumour necrosis factor antibodies associated with diseases with physiopathogenesis involving tumor necrosis factor; reagent for in vivo and/or in vitro diagnosis on the basis of murine or human, monoclonal or polyclonal anti-tumor necrosis factor antibodies linked to radionuclides; methods for diagnosing in vitro and/or in vivo diseases with physiopathogenesis involving the tumour necrosis factor, using the thus obtained reagent, and kit containing said reagent for diagnosing diseases with physiopathogenesis involving the tumour necrosis factor
05/03/2012WO2012032498A3 Meningococcus overexpressing nada and/or nhba and outer membrane vesicles derived therefrom
05/03/2012WO2012025831A3 Salmonella vaccine proteins
05/03/2012WO2012024643A3 MST1/STK4 PHOSPHO-THREONINE 120 (pMST-T120) ANTIBODY
05/03/2012WO2012019024A3 Her3-binding molecules and immunoconjugates thereof
05/03/2012WO2012018856A3 Hiv vaccine therapy with concomitant antiviral monotherapy
05/03/2012WO2012017324A3 Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
05/03/2012WO2012011731A3 Method for separating and identifying calgranulin a as a dementia marker from blood cells
05/03/2012WO2012002760A3 Method for treating and diagnosing cancer by using cell-derived microvesicles
05/03/2012WO2011163478A3 Dual variable domain immunoglobulins and uses thereof
05/03/2012WO2011161226A3 Novel antibody formulation
05/03/2012WO2011145885A3 Composition for screening and a screening method for substances active in treating hepatitis b
05/03/2012WO2011133685A3 Nanoparticle targeting to ischemia for imaging and therapy
05/03/2012WO2011130753A3 Functionalized nano- and micro-materials for medical therapies
05/03/2012WO2011120013A3 Vista regulatory t cell mediator protein, vista binding agents and use thereof
05/03/2012WO2011041336A3 Treating notch1-antagonist-resistant cancer (s) using notch3 antagonists
05/03/2012US20120109097 Recombinant il-9 antibodies and uses thereof
05/03/2012US20120107928 Antibody Inhibitors of GDF-8 and Uses Thereof
05/03/2012US20120107846 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
05/03/2012US20120107827 PSMCs As Modifiers of the RB Pathway and Methods of Use
05/03/2012US20120107408 Pharmaceutical microparticles
05/03/2012US20120107391 Therapy of platinum-resistant cancer
05/03/2012US20120107390 Feline infectious peritonitis vaccine
05/03/2012US20120107366 Block Copolymer Systems and Their Use in Medical Devices
05/03/2012US20120107364 Antibody having anti-cancer activity
05/03/2012US20120107363 Immunogen against campylobacter infection
05/03/2012US20120107362 Neurotoxins exhibiting shortened biological activity
05/03/2012US20120107361 Albumin-Free Botulinum Toxin Formulations
05/03/2012US20120107360 Gamma-glutamyl transpeptidase attenuated francisella
05/03/2012US20120107359 Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents
05/03/2012US20120107358 Subgenomic replicons of the flavivirus dengue
05/03/2012US20120107357 Novel divergent picornavirus: cosavirus
05/03/2012US20120107356 Composition useful as rotavirus vaccine and a method therefor
05/03/2012US20120107355 Method of rapidly producing improved vaccines for animals
05/03/2012US20120107354 Viral vaccine and process for preparing the same
05/03/2012US20120107353 Composition
05/03/2012US20120107352 Lipopolysaccharide of ochrobactrum intermedium and their use as immunostimulant of mammalians
05/03/2012US20120107351 In Ovo Vaccination of Campylobacter in Avian Species
05/03/2012US20120107350 Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof
05/03/2012US20120107349 Multivalent nanoemulsion vaccines
05/03/2012US20120107348 Multivalent pcv2 immunogenic compositions and methods of producing such compositions
05/03/2012US20120107347 Combination immunotherapy compositions against cancer and methods
05/03/2012US20120107346 Combination vaccines with low does of hib conjugate
05/03/2012US20120107345 Manufacture of vaccines that contain both hepatitis b virus surface antigens and surfactant
05/03/2012US20120107343 Production of recombinant proteins in ciliates and uses thereof
05/03/2012US20120107342 Ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in the method
05/03/2012US20120107341 Methods for producing an immune response to tuberculosis
05/03/2012US20120107340 Compositions for immunising against staphylococcus aureus
05/03/2012US20120107339 Chimeric Factor H Binding Proteins (fHBP) Containing a Heterologous B Domain and Methods of Use
05/03/2012US20120107338 Identification of a novel retrovirus in patients with benign prostatic hyperplasia
05/03/2012US20120107337 Novel formulations of tumour-associated peptides binding to human leukocyte antigen (hla) class i or class ii molecules for vaccines
05/03/2012US20120107335 Synthetic Oligopeptides Designed From Mite Cysteine Proteases and Methods for the Production of
05/03/2012US20120107334 Method for enhancing immune response with peptide
05/03/2012US20120107333 Vangl1 peptides and vaccines including the same
05/03/2012US20120107332 Beta-Glucuronide-Linker Drug Conjugates
05/03/2012US20120107331 Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
05/03/2012US20120107330 Antagonists, uses & methods for partially inhibiting tnfr1
05/03/2012US20120107329 EGFR and PAR2 Regulation of Intestinal Permeability
05/03/2012US20120107328 Gamma secretase modulators
05/03/2012US20120107327 Immunogenic compositions of staphylococcus aureus antigens
05/03/2012US20120107326 Neutralizing antibodies to influenza viruses
05/03/2012US20120107325 IL-17 Antagonistic Antibodies
05/03/2012US20120107324 TARGETED BINDING AGENTS DIRECTED TO a5ß1 AND USES THEREOF
05/03/2012US20120107323 Kinase protein binding inhibitors
05/03/2012US20120107322 Immunogenic and therapeutic compositions for streptococcus pyogenes
05/03/2012US20120107321 Antibodies And Epitopes Specific To Misfolded Prion Protein
05/03/2012US20120107320 Antibodies specifically directed to the soluble form of ctla-4
05/03/2012US20120107319 Pharmaceutical compositions comprising antibodies binding to the intracellular domain of EBV (Epstein-Barr virus) latent membrane protein-1 (LMP1)
05/03/2012US20120107318 Methods of administering pif agonist peptides and uses thereof
05/03/2012US20120107317 Use of cytoplasmic c-myc for regulating immune responses
05/03/2012US20120107316 Protective anti-glucan antibodies with preference for beta-1,3-glucans
05/03/2012US20120107315 Predicting progression to advanced age-related macular degeneration using a polygenic score
05/03/2012US20120107314 Cab molecules
05/03/2012US20120107313 Mammalian receptor proteins; related reagents and methods
05/03/2012US20120107312 Combinations for the Treatment of Diseases involving Cell Proliferation
05/03/2012US20120107311 Targeted identification of immunogenic peptides
05/03/2012US20120107310 Methods of antagonizing signal transduction in spinal cord cells
05/03/2012US20120107309 Polymorphism in k-ras 3' untranslated region associated with clinical outcomes of cancer treatments independent of k-ras mutation status
05/03/2012US20120107308 Gene expression levels of egfr, vegfr2, and ercc1 associated with clinical outcomes of chemotherapy
05/03/2012US20120107307 Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors
1 ... 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 ... 1823